Compare IRON & DAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | DAC |
|---|---|---|
| Founded | 2017 | 1972 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2020 | 2006 |
| Metric | IRON | DAC |
|---|---|---|
| Price | $68.20 | $129.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | $103.18 | ★ $112.50 |
| AVG Volume (30 Days) | ★ 426.0K | 85.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 3.00% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $283.52 | N/A |
| P/E Ratio | ★ N/A | $4.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.00 | $82.88 |
| 52 Week High | $99.50 | $135.21 |
| Indicator | IRON | DAC |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 56.06 |
| Support Level | $58.13 | $91.92 |
| Resistance Level | $71.53 | $135.21 |
| Average True Range (ATR) | 3.23 | 4.09 |
| MACD | -0.17 | -0.54 |
| Stochastic Oscillator | 46.09 | 35.40 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.